RECEIVED GENTRAL FAX GENTER MAY 3 0 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Binie V. Lipps
Frederick W. Lipps
Serial No.: 10/716,982

Filed: November 19, 2003

For: Saliva test for early diagnosis of cancers

\$ ATTY DCKT NO: FWLPAT019US

Art Unit: 1642

Examiner: Tidwell, Judy Lille

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following papers are being facsimile transmitted to the Patent and Trademark Office, FAX NO: 571-273-8300 on the date shown below.

1. A Response to the Requirement for Restriction dated May 8, 2006 concerning this application. (3 pages including cover)

30 May 2006

(Date)

John R. Casperson Reg. No. 28 198

REGEIVED Gentral fax genter MAY 3 0 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Binie V. Lipps
Frederick W. Lipps
Serial No.: 10/716,982

Filed: November 19, 2003

For: Saliva test for early diagnosis of cancers

S ATTY DCKT NO: FWLPAT019US

Art Unit: 1642

Examiner: Tidwell, Judy Lille

Commissioner for Patents

PO Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to a restriction requirement mailed May 8, 2006 concerning the captioned application, please consider the following:

REMARKS

Restriction has been required between claims 1-20, (Group I), directed toward a process for conducting an assay, claim 21, (Group II), directed toward a cancer diagnosis method, and claims 22-23, (Group III), directed toward a cancer treatment monitoring method. Claims 1-20, (Group I), are provisionally elected. The restriction requirement is traversed.

The basis for the restriction requirement is said to be that the claimed inventions are unrelated. However, all claims require, in various words, bringing a saliva sample together with at least least one antibody made against a proteonic cancer marker. Since all claims require this step, they are